About NeuroOncoGuides

Our Mission

Chemotherapy-induced peripheral neuropathy (CIPN) and cancer-related neurological complications affect over 68% of cancer patients undergoing neurotoxic therapy, often causing permanent loss of mobility, chronic neuropathic pain, fall trauma, and severe financial toxicity. NeuroOncoGuides was established as an open-access public health initiative to empower patients and oncology teams with evidence-based prevention strategies, clinical severity scoring, and direct matching with mobility assistance grants worldwide.

What We Provide

Clinical Condition Guides: In-depth breakdowns of Taxane neuropathy, Platinum cold allodynia, Chemo Brain (CRCI), CAR-T neurotoxicity (ICANS), Metastatic Spinal Cord Compression (MSCC), and Radiation Radionecrosis.
NCI-CTCAE Severity Grader: Standardized functional evaluation determining Grade 1-4 severity, chemo dose reduction rules, and fall hazard classification.
Cryotherapy Protocol Guide: Practical frozen glove and slipper timing and temperature guidelines during paclitaxel infusions.
Pharmacology Decoders: Mechanism, dosing titration, and clinical trial evidence for Duloxetine, Gabapentin, Pregabalin, Compounded BAK Gel, and Bevacizumab.
Non-Profit Mobility Grants: 100+ vetted charitable funds, equipment loan programs, and copay assistance foundations across 20+ countries.
Zero-Knowledge Sensory Vault: Private local storage allowing patients to track numbness progression and pain scores without cloud tracking.

Part of the OncoGuides Network

NeuroOncoGuides is the 7th portal in the unified OncoGuides network, alongside human oncology (cancer.oncoguides.org), autoimmune diseases (autoimmune.oncoguides.org), psycho-oncology (psycho.oncoguides.org), cardio-oncology (cardio.oncoguides.org), feline oncology (cats.oncoguides.org), and canine oncology (dogs.oncoguides.org).